IR/PR

Here are new updates from NovMetaPharma.
Notice
Progress of US FDA Phase 2c clinical trial

Registration date : 2020.11.20

The production of drugs to be used on US FDA Phase 2c clinical trial, scheduled for obesity and type 2 diabetes patients, was completed on June 11, 2020 and follow-up procedures are in progress. The major biomarkers in Phase 2c clinical trial consist of exploratory indicators related to type 2 diabetes, obesity, and chronic kidney disease.


Attach Files : none

  • < Prev Submission of manuscript to scientific journal
  • Next > NovDB2, IND submitted for US FDA Phase 2c clinical trial
List